Background Combination antiretroviral therapy has led to signifi cant increases in survival and quality of life, but at a population-level the eff ect on life expectancy is not well understood. Our objective was to compare changes in mortality and life expectancy among HIV-positive individuals on combination antiretroviral therapy. Interpretation Life expectancy in HIV-infected patients treated with combination antiretroviral therapy increased between 1996 and 2005, although there is considerable variability between subgroups of patients. The average number of years remaining to be lived at age 20 years was about two-thirds of that in the general population in these countries.
Introduction
Treatment with antiretroviral drugs of people infected with HIV-1 has improved signifi cantly since the introduction of combination antiretroviral therapy in 1996. In treatment-naive patients, fi rst-line combination therapy selection is generally derived from two diff erent forms of regimen, which contains either non-nucleoside reverse transcriptase inhibitors (NNRTIs) or protease inhibitors (PIs). 1 Both regimens function by suppressing viral replication and rapidly increasing CD4 cell counts. 2 Over the past decade, combination therapy regimens have become more eff ective, better tolerated, and have been simplifi ed in terms of dosing. [3] [4] [5] [6] [7] [8] Clinical trials and observational studies have shown profound reductions in mortality and morbidity in patients infected with HIV as a result of combination antiretroviral therapy. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] This decrease in mortality is particularly apparent in industrialised, high-income countries where access to health care and antiretroviral treatments is more readily available. 19 Life expectancy and mortality are universally viewed as important population health indicators. As such, several studies have displayed the negative relation between HIV prevalence and life expectancy at a population level. 20 However, the eff ect of HIV on life expectancy in the era of combination therapy is not well understood because of the relative novelty of this treatment. The objective of this study was to compare changes in mortality rates and life expectancy among HIV-positive individuals on combination therapy in high-income countries over three separate periods (1996-99, 2000-02, and 2003-05) and in subgroups defi ned by patient characteristics at initiation of such treatment.
Methods

Participants
The Antiretroviral Therapy Cohort Collaboration (ART-CC) is a multinational cohort study of anti retroviral-naive HIV-positive patients initiating com bina tion anti retroviral therapy. [21] [22] [23] The collaboration was estab- Cohort studies were eligible to join if they had enrolled at least 100 HIV-1-infected antiretroviral-naive patients aged 16 years or older who initiated potent combination therapy with at least three antiretrovirals and had been followed up for median duration of at least 1 year. All prospective studies that joined the collaboration have been approved by their local ethics committees or institutional review boards, use standardised methods of data collection, and schedule follow-up visits at least once every 6 months.
Data collection
Patient selection and data extraction were done at the data centres of the participating cohort studies. Non-nominal data from each cohort on a predefi ned set of demographic, laboratory, and clinical variables were then pooled and analysed centrally. Cohort data managers from EuroSIDA were asked to provide a unique study identifi cation for each record, since EuroSIDA patients could also be members of other cohort studies and therefore could potentially be included in the dataset twice. 14 
Between the ages 20 and 44 years 
Statistical analysis
Crude (all ages) and age-specifi c mortality rates for individuals with age between 20 and 44 years were calculated. Mortality rates (per 1000 person-years) were calculated by dividing the total number of deaths by the total number of person-years of follow-up. Mortality rates were stratifi ed by sex, transmission group (injecting drug use vs other), and baseline CD4 cell count (<100, 100-199, ≥200 cells per μL). Rates in periods defi ned by period of initiation of combination therapy and period of follow-up were internally standardised by including centred values of prognostic variables (values with mean zero) in Poisson regression models. Potential years of life lost (PYLL) were calculated as the sum of years that HIV-positive participants in our analyses lost because of premature death. 24, 25 PYLL is calculated with death before the age of 65 years being considered premature, since this is deemed to be the age at which most people retire. PYLL were expressed as per 1000 person-years from age 20 to 64 years. Values were stratifi ed by sex, transmission group, and baseline CD4 cell count.
Abridged life tables were constructed from age-specifi c mortality rates to compare life expectancies at the age of 20 years in 1996-99, 2000-02, and 2003-05. Large populations are needed to overcome systematic and random variations in mortality when building complete life tables, therefore abridged life tables were used in this study. These tables describe the mortality experience that hypothetical cohorts of HIV-positive individuals would have had if they were subjected to the mortality rates in the observed calendar periods. The life expectancy at an exact age is a demographic indicator that measures the average number of additional years that will be lived by a person after that age, according to the cross-sectional age-specifi c mortality rates for all causes of death during the study period. Life expectancy values at exact ages 20 and 35 years were reported for the total cohort as well as stratifi ed by sex, transmission group, and baseline CD4 cell count. Detailed information on the calculations of life tables, potential years of life lost, crude and age-specifi c mortality rates can be found in webappendices 2 and 3.
Analyses were done with Stata version 10.0 and Microsoft Excel 2008.
Role of the funding source
The study sponsors had no role in the design or con duct of this study, or in the collection, analysis, or interpretation of the data. The corresponding author, Margaret May, and Jonathan Sterne had full access to all the data. The corresponding author had the fi nal responsibility for the decision to submit for pub lication.
Results
Our analyses were based on 43 355 eligible patients and 2050 (4·7%) deaths from the 14 participating cohorts. Table 1 shows the distribution of baseline variables of interest according to calendar period of initiation of combination antiretroviral therapy. Because of the large sample size, there were statistically signifi cant diff erences in the distribution of all variables over the three periods studied, although the magnitudes of some diff erences were small. Over time, there were increases in median age, and in the proportion of participants who were women, who did not have a history of injecting drug use, who had CDC clinical stage A/B disease (ie, no pre-antiretroviral therapy AIDS-defi ning event), and were on non-PI-based regimens. Table 2 shows mortality rates, PYLLs, and life expectancy at ages 20 and 35 years for the entire cohort. Overall mortality rates (20 years and above), mortality rates between the ages of 20 and 44 years, and PYLLs declined between 1996-99 and 2003-05. Between 1996-99 and 2003-05, there was a gain in life expectancy for those at age 20 years of about 13 years; similar gains in life expectancy in those aged 35 years were also seen. Table 3 reports crude and internally standardised mortality rates by period of initiation and period of follow-up of combination therapy. There were declines in mortality rates by both period of initiation and period of follow-up. Table 4 shows the same health indicators as in table 2 stratifi ed by sex and transmission group (ie, injecting drug use vs non-injecting drug use). Women had lower mortality rates and PYLLs and somewhat higher life expectancies than did men. Individuals with a history of injecting drug use also had higher rates of mortality and lower life expectancy than did non-injecting drug users. Life expectancy at age 20 years and at age 35 years was Data are deaths per 1000 person-years (95% CI). *Follow-up restricted to the same period during which combination therapy was initiated. †Standardised rates were internally standardised by sex, age at initiation of combination therapy, presumed mode of transmission (injecting drug use vs other), and CD4 cell count. lower in injecting drug users than in non-injecting drug users. Table 5 displays mortality rates, PYLLs, and life expectancy stratifi ed by baseline CD4 cell count. Overall mortality rates, mortality rates between the ages of 20 and 44 years, and PYLLs decreased substantially with increasing CD4 cell count at baseline, as did life expectancy at age 20 years and at age 35 years.
Sensitivity analyses were done to examine the eff ect of cohorts from France on our estimates of life expectancy in the main analyses, since the two French cohorts (n=20 695) represent nearly half our study population and the majority of people who initiated combination therapy in France since 1996. The overall mortality rates in the French cohorts were very similar to those reported in cohorts from other countries (webtable). Life expectancy at 20 years was 43·6 years in the French cohorts and 43·0 years in non-French cohorts, and 32·5 years in French cohorts and 31·5 years in non-French cohorts at 35 years.
Discussion
Our analysis of 14 cohort studies and 43 355 HIV-infected patients indicate that there has been an improvement of outcomes with combination anti retroviral therapy between 1996 and 2005, characterised by a marked decrease in mortality rates and potential years of life lost, and by corresponding increases in life expectancy and the proportion of patients surviving from age 20 to age 44 years. Life expectancy diff ers markedly between subgroups defi ned by patient characteristics at initiation of combination therapy, and is notably lower in patients with presumed transmission via injecting drug use and who initiated treatment at lower CD4 cell counts.
Previous studies have shown similar decreases in mortality rates and increases in life expectancy as a result of combination therapy. [26] [27] [28] [29] [30] [31] [32] [33] However, such fi ndings have been restricted to countrywide analyses, and have often been localised at the provincial or state level. 30, 31 Additionally, all previous studies have been based on substantially smaller samples. One of the larger studies, which took place in the USA, analysed a cohort of nearly 5000 HIV-infected patients and exhibited similar survival benefi ts for individuals being treated with combination antiretroviral therapy. 29 However, the study did not take into account previous exposure to antiretroviral therapy before initiation of combination treatment, which may be a confounding factor. By contrast, all patients in our analysis were treatment naive at initiation of combination therapy.
The progressive reductions in mortality and gains in life expectancy over the three periods studied here are probably the result of both improvements in therapy during the fi rst decade of combination therapy and continuing declines in mortality rates among individuals on such treatment for long periods. These results lend further credence to earlier reports. In a recent study by Lima and colleagues, 31 2238 HIV-infected antiretroviralnaive patients initiating therapy in British Columbia, Canada, were surveyed over several periods between 1993 and 2004. The authors noted the vast improvements in drug regimens since the pre-combination antiretroviral therapy era as well as over the course of development of combination treatment. In the early era of antiretroviral therapy, monotherapies were the main form of treatment. Since the advent of combination antiretroviral therapy, triple antiretroviral combinations have become the standard of care for HIV-infected patients in high-income countries and have improved substantially as treatments developed. These advances in treatment have transformed HIV from being a fatal disease, which was the reality for patients before the advent of combination treatment, into a long-term chronic con dition. In fact, a number of studies have found that AIDS-defi ning illnesses as the cause of death are declining dramatically: 27, 34, 35 Because of improvements in treatment, fewer HIV-infected patients are dying of characteristic HIV-related illnesses, such as non-Hodgkin lymphoma. 36 Despite these reassuring results, there is still a large discrepancy between the life expectancy of the general population and the life expectancy of an HIV-infected individual. A person starting combination therapy can expect to live about 43 years at 20 years of age, about two-thirds as long as the general population in these countries. This discrepancy in life expectancy could be attributed to active HIV infection or to other underlying lifestyle, socioeconomic, and health issues. Further research must be devoted to the ongoing improvement of antiretroviral therapy to lessen the gap between the life expectancy of HIV-infected patients and the general population, as well as to improve the quality of life of individuals living with HIV.
There is also considerable heterogeneity between subgroups in life expectancy. For example, the disparity in life expectancy between HIV-infected injecting drug users and non-injecting drug users is very large. This fi nding is consistent with previous fi ndings. 32, 37 There may be several reasons for this discrepancy, such as issues of adherence, inadequate or unequal access to treatment, active illicit drug use, hepatitis C co-infection, higher rates of smoking and alcohol use, and socioeconomic status. 38 The increasing proportion of women starting combination therapy could be the result of migration of women infected through heterosexual sex in sub-Saharan Africa: a number of settings have reported higher numbers of sub-Saharan African women accessing therapy in the past few years. 39 Higher life expectancy in women could be due to the higher median baseline CD4 cell count in women, because women tend to be diagnosed earlier in the course of their infection, in antenatal settings.
Our life expectancy results are representative of all individuals who started combination therapy, including those who did not remain on such treatment throughout follow-up. Therefore, the changes in mortality and life expectancy over time might refl ect not only the long-term tolerability and diminishing side-eff ects of antiretroviral drugs, but also reductions in rates of treatment discontinuation and nonadherence. A previous article 40 found little evidence that short-term (1 year) survival had improved between 1996 and 2003, despite an improvement in virological response after initiation of combination therapy. The reductions in mortality rates and corresponding improvements in life expectancy seen here probably refl ect both improvements in 3 year survival apparent in the extended and updated dataset analysed here, and the continuing declines in mortality rates among patients on combination therapy for extended periods.
Our study is potentially limited by the under-reporting of deaths by some cohorts that do not actively link to administrative records. Such under-reporting could imply that the mortality rates reported here are underestimates. The reporting methods among the cohorts participating in this study were not the same; some cohorts used record linkages done with vital statistics, while others used self-reporting systems to monitor mortality rates. We were reassured by the lack of diff erence in mortality rates between the French and non-French cohorts. Furthermore, we were not able to distinguish between active and a history of injecting drug use or the eff ect of subsequent changes in antiretroviral therapy over the period of observation. We do not have detailed data on causes of death, although we are currently collecting available information for all patients and, where possible, using this to categorise causes of death. Preliminary data suggest that 85% of patients who died had some information on cause of death. Of these, about 50% died of an AIDS-defi ning condition. Other major causes of death included non-AIDS malignancy, heart disease, infection, violent causes (including suicide and substance abuse), and liver-related causes. Lastly, the estimation of mortality in the last open interval (65 years and more) is diffi cult because the person-years of follow-up in this interval is limited-few patients in our study are over the age of 65 years and those patients who are enrolled tend to be younger (within this age-group) than those in the general population. Therefore, mortality rates were adjusted in this open interval to limit the eff ect of the under ascertainment of deaths (webappendix 2). Our results are similar to those reported from Denmark for people on treatment since the mid-1990s. 41 However, extended follow-up of older HIV-infected patients treated with combination antiretroviral therapy will be needed to produce reliable estimates of mortality rates in these groups, and improved estimates of life expectancy for all patients.
In summary, the results of this study indicate that people living with HIV in high-income countries can expect increasing positive health outcomes on combination antiretroviral therapy. The marked increase in life expectancy since 1996 is a testament to the gradual improvement and overall success of such treatment. Because there is still a large discrepancy in life expectancy between the general population and HIV-infected individuals, we encourage health planners to use these data to improve health services and living conditions for such people. Cohort studies must continue to observe and monitor individuals initiating combination antiretroviral therapy to monitor long-term eff ects and toxicities.
